Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma

ClinicalTrials.gov ID: NCT02371746

Public ClinicalTrials.gov record NCT02371746. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-Center, Three-Stage, Open-Label, Prospective, Active-Comparator-Controlled Phase 2a Study of ENV515 (Travoprost) Intracameral Implant in Patients With Bilateral Ocular Hypertension or Early Primary Open-Angle Glaucoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a multiple cohort study that will evaluate the safety and efficacy of ENV515 travoprost XR in patients with open-angle glaucoma or ocular hypertension.

Study identification

NCT ID: NCT02371746
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Envisia Therapeutics; Industry
Enrollment: 41 participants

Conditions and interventions

Conditions

Glaucoma and Ocular Hypertension

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 85 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 1, 2015 (Actual)
Primary completion: Feb 13, 2019 (Actual)
Completion: Feb 13, 2019 (Actual)
Last update posted: Oct 17, 2019

2015 – 2019

United States locations

U.S. sites: 14
U.S. states: 9
U.S. cities: 14

Facility	City	State	ZIP	Site status
Not listed	Chandler	Arizona	85225	—
Not listed	Garden Grove	California	92843	—
Not listed	Inglewood	California	90301	—
Not listed	Redding	California	96002	—
Not listed	Morrow	Georgia	30260	—
Not listed	Indianapolis	Indiana	46260	—
Not listed	Chesterfield	Missouri	63017	—
Not listed	Kansas City	Missouri	64133	—
Not listed	Cincinnati	Ohio	45242	—
Not listed	Portland	Oregon	97210	—
Not listed	Sioux Falls	South Dakota	57108	—
Not listed	Austin	Texas	78731	—
Not listed	Houston	Texas	77025	—
Not listed	San Antonio	Texas	78229	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02371746, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 17, 2019 · Synced Oct 22, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02371746 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →